Molecular diagnostics in clinical oncology: an overview
Молекулярная диагностика в клинической онкологии: обзор
2025-07-17
SCID: 54.1/pktggfkk
Discuss with AI
circulating tumor DNA (ctDNA)germline pathogenic variantsliquid biopsymolecular diagnosticspredictive tests for drug-target matching
Figures from the paper
Abstract (AI)
Molecular diagnostics has become an integral part of modern clinical oncology. There are several dozen hereditary cancer syndromes; the detection of germline pathogenic variants in tumor-predisposing genes allows for the identification of subjects at-risk as well as guides the administration of cytotoxic and targeted drugs. The development of predictive tests for personalized drug-target matching is the best-known achievement of molecular oncology. For the time being, these assays are routinely utilized for the management of lung, breast, ovarian, colorectal, thyroid, biliary tract, endometrial, urothelial, and other malignancies. We are currently witnessing the emergence of practical applications of liquid biopsy. The detection of circulating tumor DNA (ctDNA) is a highly sensitive and specific procedure, which is currently used for the detection of secondary drug-resistant mutations, and holds great promise for the monitoring of malignant disease in oncological patients and early cancer detection in healthy individuals. While the utilization of molecular tests is currently limited to particular categories of cancer patients, their use is likely to become significantly more widespread in the near future. This trend will affect educational standards, requiring practicing physicians to become more familiar with molecular biology, and, vice versa, claiming some fluency in clinical oncology from laboratory specialists.
Key Findings
1
Current use of molecular tests is limited to particular cancer patient categories, but their clinical application is expected to become significantly more widespread.
2
Detection of germline pathogenic variants in tumor-predisposing genes enables identification of at-risk individuals and guides cytotoxic and targeted drug administration.
3
Liquid biopsy and detection of circulating tumor DNA (ctDNA) are highly sensitive and specific for detecting secondary drug-resistant mutations and show promise for disease monitoring and early cancer detection.
4
Predictive molecular tests for personalized drug-target matching are established and routinely used in management of lung, breast, ovarian, colorectal, thyroid, biliary tract, endometrial, urothelial, and other malignancies.
5
Wider adoption of molecular diagnostics will require updated education: clinicians need greater molecular biology knowledge and laboratory specialists need increased clinical oncology fluency.
Research Object
Molecular diagnostic assays (including germline testing and circulating tumor DNA/liquid biopsy) used in clinical oncology
Research Subject
Their applications and clinical utility for identifying hereditary cancer predisposition, guiding targeted and cytotoxic therapy selection, detecting secondary drug-resistant mutations, monitoring malignant disease, and early cancer detection
Publication Details
Publication Date
2025-07-17
Journal
Publisher
ISSN
Cited by
2
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer2016
Liquid biopsy in cancer: current status, challenges and future prospects2024
Tumor biomarkers for diagnosis, prognosis and targeted therapy2024
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics2025